Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesOngoing Landmark ROADMAP Study Demonstrates Significant Improvement in Blood Pressure Control at One Year, According to Blinded Results
Daiichi Sankyo, 05/11/09
Blinded one-year blood pressure (BP) reduction data from the ongoing landmark study ROADMAP, were presented today at the American Society of Hypertension Twenty-Fourth Annual Scientific Meeting and Exposition in San Francisco. ROADMAP is the first-ever large-scale clinical trial, being conducted in 19 European countries to evaluate whether the angiotensin II receptor blocker olmesartan medoxomil can prevent the onset of microalbuminuria in patients with type 2 diabetes. Microalbuminuria is an early sign of kidney disease, as well as an important risk factor of cardiovascular disease. The secondary objective of the ROADMAP trial includes incidence of cardiovascular and renal morbidity and mortality. A qualitative parameter in the secondary objective was to measure cuff blood pressure (BP)
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
Second Pivotal Phase III Study of Gileads Darusentan for Resistant Hypertension Misses Primary Endpoints
Gilead, 12/15/09
Annual Progression of Coronary Calcification in Trials of Preventive Therapies
Archives of Internal Medicine, 12/15/09
Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6·4 years
The Lancet, 12/15/09
Today in Major Studies...keeping you current
Receive free subspecialty "5-minute updates" via email
Evaluation of Treatment Satisfaction in Children with Allergic Disease Treated with an Antihistamine: An International, Non-Interventional, Retrospective Study
Clinical Drug Investigation, 12/11/09
Sanofi Pasteur Global Dengue Vaccine Clinical Program Expanded in Latin America
Sanofi-aventis, 12/10/09
Allos Therapeutics' FOLOTYN Shows Activity in a Dose Finding Phase 1 Study of Relapsed or Refractory Cutaneous T-Cell Lymphoma
Allos Therapeutics, 12/09/09
Sponsor
Article Search
Sponsor
Sponsor